Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

ER+ and AR+ Breast Cancer 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × ostarine × Clear all
NCT02746328 2024-02-26

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

GTx

Phase 2 Withdrawn
Breast

ER+ and AR+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡